Regeneron – Talk Bio

Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity

1 day ago talkbio0Tagged Biological Factors, Boost, Capacity, CDMO, Fujifilm, Manufacture, Regeneron, United States

Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost

FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD

3 days ago talkbio0Tagged Age related macular degeneration, Diabetic Retinopathy, dosing, Extension, Eylea HD, Interval, Regeneron, Rejection, United States Food and Drug Administration

United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy

A closer look at pharmas top patent losses in 2025

1 month ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market

1 month ago talkbio0Tagged amgen, Amgen 's, court, Eylea, Eylea biosimilar, Federal Circuit, Market, Pavblu, Regeneron

Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

3 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.